These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26327766)

  • 1. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence.
    Qiu Q; Duan XW; Li Y; Yang LK; Chen Y; Li H; Duan ZP; Wang L
    World J Gastroenterol; 2015 Aug; 21(32):9588-97. PubMed ID: 26327766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China.
    Qiu Q; Li Y; Duan XW; Yang LK; Chen Y; Li H; Wang L; Duan ZP
    PLoS One; 2014; 9(10):e109652. PubMed ID: 25329072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
    Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
    J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Patient Reimbursement Timing and Patient Out-of-Pocket Expenses on Medication Adherence in Patients Covered by Private Drug Insurance Plans.
    Després F; Forget A; Kettani FZ; Blais L
    J Manag Care Spec Pharm; 2016 May; 22(5):539-47. PubMed ID: 27123915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.
    Li M; Kong YY; Wu SS; Zhou JL; Wu XN; Wang L; Su JT; Ou XJ; You H; Xie XQ; Wei ZH; Jia JD
    J Dig Dis; 2019 Sep; 20(9):467-475. PubMed ID: 31231938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
    Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
    Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement policies in the Asia-Pacific for chronic hepatitis B.
    Lim SG; Amarapurkar DN; Chan HL; Crawford DH; Gane EJ; Han KH; Ahn SH; Jafri W; Jia J; Kao JH; Lesmana LA; Lesmana CR; Mohamed R; Phiet PH; Piratvisuth T; Sarin SK; Sollarno JD; Eguchi Y; Mahtab MA; Lee KH
    Hepatol Int; 2015 Jan; 9(1):43-51. PubMed ID: 25788378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China.
    Yong M; Xianjun X; Jinghu L; Yunyun F
    Aust Health Rev; 2018 Feb; 42(1):39-44. PubMed ID: 28263706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drug utilization and annual expenditures for patients with chronic HBV infection in Guangzhou, China, in 2008-2015.
    Zhou F; Jia W; Yang S; Chen G; Li G; Li Y; Liang Y; Yang Y; Gao Y; Chen Y
    Antivir Ther; 2019; 24(6):405-416. PubMed ID: 31348006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece.
    Voulgaris T; Vlachogiannakos J; Ioannidou P; Papageorgiou MV; Zampeli E; Karagiannakis D; Georgiou A; Papazoglou A; Karamanolis G; Papatheodoridis GV
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):264-270. PubMed ID: 27922484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
    Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
    J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B.
    Xu K; Liu LM; Farazi PA; Wang H; Rochling FA; Watanabe-Galloway S; Zhang JJ
    Glob Health Action; 2018; 11(1):1433987. PubMed ID: 29447614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
    Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
    Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with non-adherence to HBV antiviral therapy.
    Sheppard-Law S; Zablotska-Manos I; Kermeen M; Holdaway S; Lee A; George J; Zekry A; Maher L
    Antivir Ther; 2018; 23(5):425-433. PubMed ID: 29355830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.
    Power TP; Ke X; Zhao Z; Bonine NG; Cziraky MJ; Grabner M; Barron JJ; Quimbo R; Vangerow B; Toth PP
    Vasc Health Risk Manag; 2018; 14():23-36. PubMed ID: 29440909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
    Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
    Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
    Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
    Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.